Drug intelligence / Profile preview

Afala

Development stage
Unknown
Lead developer
Materia Medica Holding
Modality
Antibody-Based Therapeutics
Administration
Sublingual
01

Overview

Afala is an over-the-counter (OTC) homeopathic and release-active medication developed by Materia Medica Holding for the treatment of prostate disorders. The active ingredient consists of affinity-purified antibodies to prostate-specific antigen (PSA) in ultra-low doses, prepared using homeopathic dilutions (C12, C30, and C200). Its mechanism of action involves the modification of the functional activity of endogenous PSA, which regulates the proliferative activity of prostate cells and provides anti-inflammatory, anti-edema, and analgesic effects. Afala is indicated for the treatment of chronic prostatitis (both bacterial and abacterial) and benign prostatic hyperplasia (BPH) stages I and II, particularly when these conditions are accompanied by dysuric disorders. Clinical studies have shown that it can help reduce prostate volume and improve urodynamics.

Brand names
AfalaАфала
Other names
Antibodies to prostate-specific antigen affinity purifiedRelease-active antibodies to PSA
02

Targets

NOS3 (eNOS)PSA (Puromycin-sensitive aminopeptidase)

Beyond the preview

Go deeper on Afala.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Afala.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call